Von Willebrand Factors (Vonvendi [von Willebrand factor {recombinant}], Wilate [von Willebrand factor/coagulation factor VIII complex {human}])

Vonvendi and Wilate are covered only for their FDA‑approved uses—on‑demand bleeding control, perioperative management, and routine prophylaxis—with product-specific age/severity limits (Vonvendi: adults only, prophylaxis only for severe Type 3 VWD; Wilate: VWD prophylaxis ≥6 years, Wilate for hemophilia A in adolescents/adults); uses outside these indications are not covered. Authorization requires prescription by or consultation with a hematologist/hemophilia specialist, documentation of diagnosis/indication, IV administration, 12‑month approval, perioperative FVIII:C and VWF:RCo assessments within 3 hours (or weight‑based dosing if unavailable) and adherence to required dosing/weight calculations and to give rFVIII if FVIII:C is below target.

"Vonvendi is a recombinant von Willebrand factor indicated for use in adults diagnosed with von Willebrand disease (VWD) for: On-demand treatment and control of bleeding episodes; Perioperative mana..."